Assessment of Bone Response After LHRH-A and Enzalutamide Plus Minus Zoledronic Acid in Prostate Cancer Patients With Hormone Sensitive Metastatic Bone Disease: a Prospectic, Phase II, Randomized, Multicenter Study

Trial Profile

Assessment of Bone Response After LHRH-A and Enzalutamide Plus Minus Zoledronic Acid in Prostate Cancer Patients With Hormone Sensitive Metastatic Bone Disease: a Prospectic, Phase II, Randomized, Multicenter Study

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Enzalutamide (Primary) ; Zoledronic acid (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms BonEnza
  • Most Recent Events

    • 15 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top